• William Y Shi, Sheila Li, Nicholas Collins, David B Cottee, Bruce C Bastian, Allen N James, and Ross Mejia.
• Department of Cardiothoracic Surgery, John Hunter Hospital, Newcastle, NSW, Australia; Department of Cardiovascular Medicine, John Hunter Hospital, Newcastle, NSW, Australia; The University of Melbourne, Australia. Electronic address: william.y.shi@gmail.com.
• Heart Lung Circ. 2015 Jul 1;24(7):667-72.

AbstractLevosimendan, a calcium sensitiser, has recently emerged as a valuable agent in the peri-operative management of cardiac surgery patients. Levosimendan is a calcium-sensitising ionodilator. By binding to cardiac troponin C and reducing its calcium-binding co-efficient, it enhances myofilament responsiveness to calcium and thus enhances myocardial contractility without increasing oxygen demand. Current evidence suggests that levosimendan enhances cardiac function after cardiopulmonary bypass in patients with both normal and reduced left ventricular function. In addition to being used as post-operative rescue therapy for low cardiac output syndrome, a pre-operative levosimendan infusion in high risk patients with poor cardiac function may reduce inotropic requirements, the need for mechanical support, the duration of intensive care admissions as well as post-operative mortality. Indeed, it is these higher-risk patients who may experience a greater degree of benefit. Larger, multicentre randomised trials in cardiac surgery will help to elucidate the full potential of this agent.Copyright © 2015 Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. All rights reserved.

23 keywords...

hide…